INTRODUCTION
Sarcoidosis is a granulomatous disease that affects multiple organs including the lungs, eyes, nerves, and skin.
Cosmetic tattooing has been frequently cited as a predisposing factor for sarcoidosis. Foreign materials such as pigments in the tattoo ink, stimulate the body's immune system in a genetically susceptible person. Chronic lowgrade exposure of the immune system to repeated cosmetic tattooing can lead to systematized granulomatous hypersensitivity, with a long latency period (1) (2) (3) . Similar to other cases of hypersensitivity, avoiding the causative antigen in this case may result in remission of symptoms (2) . However, in some cases, such as cosmetic tattooing, exposure to the antigen cannot be avoided, and hence, more invasive approaches are necessary.
There is no consensus regarding the indication and duration of the treatment for sarcoidosis. Treatment is usually recommended in patients with aggravated respiratory symptoms, especially shortness of breath and cough. Other reasons for treatment include signs of reduced lung function as determined through pulmonary function tests, or difficulty in performing daily activities due to fever, weakness, fatigue, joint pain, nervous system changes, disfiguring skin disease, or disease affecting the upper airway.
Although the disease remits spontaneously in most patients, 10 to 30% of patients develop chronic disease that could be refractory to multiple lines of treatment (4) .
Although there is minimal evidence-based data for pharmacologic management of sarcoidosis, a stepwise Here, we present the case of a 47-year-old woman with refractory systemic sarcoidosis that was induced by eyebrow tattooing and was successfully treated with adalimumab, a recombinant human IgG1 monoclonal antibody that binds specifically to TNF-alpha.
CASE SUMMARIES
A 47-year-old woman with no significant medical history was referred to our center with pain in the interphalangeal joints of the hands and the knees and and there was still no clarity on how long the therapy will continue. As we attempted to increase the injection interval once, it led to the recurrence of symptoms. Eventually, we had to reduce the interval to 2 weeks again, which indicates that the decision to reduce the injection interval should not be rushed.
A well-defined anti-TNF therapeutic strategy for refractory sarcoidosis needs to be established for further investigation.
